Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler

225 Candler Drive
Savannah, GA 31405
912-819-5704 (p)
www.sjchs.org

driving directions

Clinical Trials
Testing the Addition of a Blood Pressure Medication, Carvedilol, to HER-2 Targeted Therapy for Metastatic Breast Cancer to Prevent Cardiac Toxicity
Cancer Type: Breast Cancer

Comparing Overall Survival using Markers to Direct Cancer Monitoring versus Usual Monitoring in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer
Cancer Type: Breast Cancer

T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Cancer Type: Breast Cancer

Testing the Usual Treatment of Radiation Therapy and Hormonal Therapy to Hormonal Therapy alone for Low-Risk, Early Stage Breast Cancer, the DEBRA Trial
Cancer Type: Breast Cancer

Pembrolizumab versus Observation in Patients with Early Stage Triple-Negative Breast Cancer who had a Pathologic Complete Response after Chemotherapy plus Pembrolizumab, OptimICE-PCR Trial
Cancer Type: Breast Cancer

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early Triple Negative Breast Cancer
Cancer Type: Breast Cancer

Testing the Addition of Chemotherapy to the Usual Treatment of Ovarian Function Suppression plus Hormonal Therapy in Premenopausal ER-Positive/HER2-Negative Breast Cancer Patients Who Are At High Risk of Cancer Returning, OFSET Trial
Cancer Type: Breast Cancer

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
Cancer Type: Breast Cancer

Comparing Oral Drug Dosing Strategies in Older Patients with Metastatic Breast Cancer to Maximize Tolerance and Reduce Discontinuation: the CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Cancer Type: Breast Cancer

An Internet-based Program to Help Cancer Survivors Manage Pain (IMPACTS)
Cancer Type: Cancer Control

An Observational Research Study to Uncover Subtypes of Cancer Cachexia, LOTUS-CC Study
Cancer Type: Colon/Rectal Cancer

Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type: Gynecologic Cancers

National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type: Leukemia

Biomarker-Driven Therapy and Immunotherapy in Screening Participants with Recurrent or Stage IV Non-Small Cell Lung Cancer (The Expanded Lung-MAP Screening Trial)
Cancer Type: Lung Cancer

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial
Cancer Type: Lung Cancer

Testing Whether the Use of Brain Scans Alone Instead of Brain Scans plus Preventive Brain Radiation Affects Lifespan in Patients with Small Cell Lung Cancer
Cancer Type: Lung Cancer

National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type: Lung Cancer

Osimertinib with or without Bevacizumab as Initial Treatment for Patients with EGFR-Mutant Lung Cancer
Cancer Type: Lung Cancer

Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients who are PD-L1 Negative
Cancer Type: Lung Cancer

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer that has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Cancer Type: Lung Cancer

An Observational Research Study to Uncover Subtypes of Cancer Cachexia, LOTUS-CC Study
Cancer Type: Lung Cancer

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Cancer Type: Lung Cancer

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Cancer Type: Lung Cancer

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
Cancer Type: Melanoma

National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type: Multiple Myeloma

Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type: Ovarian Cancer

National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type: Plasma cell neoplasm

Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type: Primary Peritoneal Cancer

National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type: Prostate Cancer

Two Studies for Patients with High Risk Prostate Cancer Testing Less Intense Treatment for Patients with a Low Gene Risk Score and Testing a More Intense Treatment for Patients with a High Gene Risk Score, The PREDICT-RT Trial
Cancer Type: Prostate Cancer

Two Studies for Patients with Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients with a Low Gene Risk Score and Testing a More Intense Treatment for Patients with a Higher Gene Risk Score, The Guidance Trial
Cancer Type: Prostate Cancer

Division of Cancer Prevention NH-DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Cancer Type: Quality of Life

National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type: Solid Tumor

Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Cancer Type: Solid Tumor

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Cancer Type: Solid Tumor

Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors
Cancer Type: Solid Tumor

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
Cancer Type: Unknown Primary

Comparing Overall Survival using Markers to Direct Cancer Monitoring versus Usual Monitoring in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer
Cancer Type: Unknown Primary

Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type: Unknown Primary

Osimertinib with or without Bevacizumab as Initial Treatment for Patients with EGFR-Mutant Lung Cancer
Cancer Type: Unknown Primary

Two Studies for Patients with High Risk Prostate Cancer Testing Less Intense Treatment for Patients with a Low Gene Risk Score and Testing a More Intense Treatment for Patients with a High Gene Risk Score, The PREDICT-RT Trial
Cancer Type: Unknown Primary

Testing the Usual Treatment of Radiation Therapy and Hormonal Therapy to Hormonal Therapy alone for Low-Risk, Early Stage Breast Cancer, the DEBRA Trial
Cancer Type: Unknown Primary

Two Studies for Patients with Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients with a Low Gene Risk Score and Testing a More Intense Treatment for Patients with a Higher Gene Risk Score, The Guidance Trial
Cancer Type: Unknown Primary

Pembrolizumab versus Observation in Patients with Early Stage Triple-Negative Breast Cancer who had a Pathologic Complete Response after Chemotherapy plus Pembrolizumab, OptimICE-PCR Trial
Cancer Type: Unknown Primary

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early Triple Negative Breast Cancer
Cancer Type: Unknown Primary

Testing the Addition of Chemotherapy to the Usual Treatment of Ovarian Function Suppression plus Hormonal Therapy in Premenopausal ER-Positive/HER2-Negative Breast Cancer Patients Who Are At High Risk of Cancer Returning, OFSET Trial
Cancer Type: Unknown Primary

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
Cancer Type: Unknown Primary

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Cancer Type: Unknown Primary